The Ginkgo biloba extract EGb 761®and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background and purpose: Experimental and clinical data suggest that extracts of Ginkgo biloba improve cognitive function. However, the neurochemical correlates of these effects are not yet fully clarified. The purpose of this study was to examine the effects of acute and repeated oral administration of the standardized extract EGb 761®on extracellular levels of dopamine, noradrenaline and serotonin (5‐HT), and the dopamine metabolites 3,4‐dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the prefrontal cortex (PFC) and striatum of conscious rats. Experimental approach: Monoamines and their metabolites were monitored by the use of microdialysis sampling and HPLC with electrochemical or fluorescence detection. Key results: A single oral dose of EGb 761 (100 mg·kg−1) had no effect on monoamine levels. However, following chronic (100 mg·kg−1/14 days/once daily) treatment, the same dose significantly increased extracellular dopamine and noradrenaline levels, while 5‐HT levels were unaffected. Chronic treatment with EGb 761 showed dose‐dependent increases in frontocortical dopamine levels and, to a lesser extent, in the striatum. The extracellular levels of HVA and DOPAC were not affected by either acute or repeated doses. Treatment with the main constituents of EGb 761 revealed that the increase in dopamine levels was mostly caused by the flavonol glycosides and ginkgolide fractions, whereas bilobalide treatment was without effect. Conclusions and implications: The present results demonstrate that chronic but not acute treatment with EGb 761 increased dopaminergic transmission in the PFC. This finding may be one of the mechanisms underlying the reported effects of G. biloba in improving cognitive function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545 · cited 1×
“…and related mood disorders, whereas the progressive impairment of learning and memory functions, observed in Alzheimer’s disease, is strongly associated with the atrophy and loss of cholinergic neurons in the basal forebrain (Bartus et al., 1982; Coyle et al., 1983; Terry and Buccafusco, 2003).”
BackgroundCellular basis of working memory
Goldman-Rakic, P. S. (1995) · Neuron · doi:10.1016/0896-6273(95)90304-6 · Cited by 2,663 · cited 1×
“A body of evidence exists for the role of prefrontal cortical dopamine and dopamine receptors in modulating the neurons essential for working memory (Goldman-Rakic, 1995; Goldman-Rakic et al., 2000; Castner and Goldman-Rakic, 2004; Paspalas and Goldman-Rakic, 2005).”
BackgroundGuide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947
Modulation of memory fields by dopamine Dl receptors in prefrontal cortex
Williams, G. V., & Goldman-Rakic, P. S. (1995) · Nature · doi:10.1038/376572a0 · Cited by 1,593
Cognitive Deficit Caused by Regional Depletion of Dopamine in Prefrontal Cortex of Rhesus Monkey
Brozoski, T. J., Brown, R. M., Rosvold, H. E., & Goldman, P. S. (1979) · Science · doi:10.1126/science.112679 · Cited by 1,500
Terry, A. V., & Buccafusco, J. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041616 · Cited by 1,159 · cited 2×
“The monoamines noradrenaline, 5-HT and, possibly, dopamine are traditionally implicated in the aetiology of depression and related mood disorders, whereas the progressive impairment of learning and memory functions, observed in Alzheimer’s disease, is strongly associated with the atrophy and loss of cholinergic neuron…”
BackgroundWeikop, P., Kehr, J., & Scheel-Krüger, J. (2004) · Journal of Psychopharmacology · doi:10.1177/026988110401800311 · Cited by 57 · cited 1×
“In addition, blockade of a2-adrenoceptors with the a2-antagonist idazoxan was shown to preferentially increase extracellular dopamine levels in the PFC (Hertel et al., 1999) and potentiate the effects of venlafaxine on dopamine and noradrenaline levels (Weikop et al., 2004).”
BackgroundSelf-citation
Cited by
Dominguez, L. J., Veronese, N., Vernuccio, L., Catanese, G., Inzerillo, F., Salemi, G., & Barbagallo, M. (2021) · Nutrients · doi:10.3390/nu13114080 · Cited by 433
Tan, M.-S., Yu, J.-T., Tan, C.-C., Wang, H.-F., Meng, X.-F., Wang, C., Jiang, T., Zhu, X.-C., & Tan, L. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140837 · Cited by 253
Ginkgo biloba Extracts: A Review of the Pharmacokinetics of the Active Ingredients
Ude, C., Schubert-Zsilavecz, M., & Wurglics, M. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0074-5 · Cited by 246
“Treatment with EGb 761 and its main constituent flavonoids during 14 days increased the dopamine concentration in the extracellular fluid of the prefrontal cortex of awake rats in a dose-dependent manner [93].”
BackgroundDo polyphenols enter the brain and does it matter? Some theoretical and practical considerations
Schaffer, S., & Halliwell, B. (2012) · Genes & Nutrition · doi:10.1007/s12263-011-0255-5 · Cited by 178
Interactions between Food and Drugs, and Nutritional Status in Renal Patients: A Narrative Review
D’Alessandro, C., Benedetti, A., Di Paolo, A., Giannese, D., & Cupisti, A. (2022) · Nutrients · doi:10.3390/nu14010212 · Cited by 66
Metadata
- Authors
- Yoshitake, T., Yoshitake, S., & Kehr, J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2010-02
- Volume
- 159
- Issue
- 3
- Pages
- 659-668
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2161816639
- Cited by
- 136
- References
- 7
- FWCI
- 22.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.